Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q2 EPS by 4c ; Offers Guidance

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q2 EPS of $0.23, $0.04 better than the analyst estimate of $0.19. Revenue for the quarter came in at $156.79 million versus the consensus estimate of $145.28 million.

GUIDANCE:

Kiniksa Pharmaceuticals, Ltd. sees FY2025 revenue of $625-640 million, versus the consensus of $604 million.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Danone SA (BN:FP) (DANOY) PT Raised to EUR63 at Deutsche Bank
• Trifecta Gold closes $1.66M private placement for Yukon exploration